ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
July 21, 2021Takeda Pharmaceutical Company Limited today announced the results of a phase 3 trial investigating the efficacy and safety of recombinant von Willebrand factor (rVWF) prophylaxis,1 one of the 12 abstracts being presented at the International Society.
Pharma Sources Insight January 2025
